The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Patrick Serruys

Showing 1-20 of 545 articles
Understanding the past, getting prepared for the future. (Going from in vivo to in vitro to in silico)
Serruys P, Elkoumy A, Soliman O
November 19, 2021 | 10.4244/EIJV17I10A136
Coronary interventions
Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial
Hara H, Kawashima H, Ono M, Takahashi K, Mack M, Holmes D, Morice M, Davierwala P, Mohr F, Thuijs D, Kappetein A, O'Leary N, van Klaveren D, Onuma Y, Serruys P
October 21, 2021 | 10.4244/EIJ-D-21-00415
Age and functional relevance of coronary stenosis: a post hoc analysis of the ADVISE II trial
Faria D, Lee J, van der Hoef T, Mejía-Rentería H, Echavarría-Pinto M, Baptista S, Cerrato E, Garcia-Garcia H, Davies J, Onuma Y, Samady H, Piek J, Serruys P, Lerman A, Escaned J
October 20, 2021 | 10.4244/EIJ-D-20-01163
A Comparison of Risk Prediction Models for Patients with Acute Coronary Syndromes
Hara H, O'Leary N, Ono M, Onuma Y, Serruys P
August 17, 2021 | 10.4244/EIJ-D-21-00536
Interventions for valvular disease
Chronic Hemodynamic Performance of a Biorestorative Transcatheter Heart Valve in an Ovine Model
Serruys P, Kawashima H, Chang C, Modolo R, Wang R, de Winter R, Van Hauwermeiren H, El-Kurdi M, van den Bergh W, Cox M, Onuma Y, Flameng W, Soliman O
July 20, 2021 | 10.4244/EIJ-D-21-00386
Geographical variations in left main coronary artery revascularisation: a pre-specified analysis of the EXCEL trial
Myat A, Hildick-Smith D, de Belder A, Trivedi U, Crowley A, Morice M, Kandzari D, Lembo N, Brown W, Serruys P, Kappetein A, Sabik J, Stone G
July 2, 2021 | 10.4244/EIJ-D-21-00338
Coronary interventions
Optimal Dual Antiplatelet Therapy Duration for Bioresorbable Scaffolds: an Individual Patient Data Pooled Analysis of the ABSORB Trials
Azzalini L, Ellis SG, Kereiakes D, Kimura T, Gao R, Onuma Y, Chevalier B, Dressler O, Crowley A, Zhou Z, Redfors B, Serruys P, Stone G
June 8, 2021 | 10.4244/EIJ-D-21-00263
Coronary interventions
Impact of the CABG SYNTAX score on all-cause death at 10 years: a SYNTAX Extended Survival (SYNTAXES) substudy
Takahashi K, Thuijs D, Hara H, Wang R, Mohr F, Morice M, Holmes D, Kappetein A, Head S, Onuma Y, Serruys P
May 16, 2021 | 10.4244/EIJ-D-20-00170
Coronary interventions
Statistical methods for composite endpoints
Hara H, van Klaveren D, Kogame N, Chichareon P, Modolo R, Tomaniak M, Ono M, Kawashima H, Takahashi K, Capodanno D, Onuma Y, Serruys P
April 2, 2021 | 10.4244/EIJ-D-19-00953
Coronary interventions
Impact of clinical and haemodynamic factors on coronary flow reserve and invasive coronary flow capacity in non-obstructed coronary arteries: a patient-level pooled analysis of the DEBATE and ILIAS studies
Stegehuis V, Wijntjens G, Bax M, Meuwissen M, Chamuleau S, Voskuil M, Koch K, Di Mario C, Vrints C, Haude M, Boersma E, Serruys P, Piek J, van der Hoef T
April 2, 2021 | 10.4244/EIJ-D-19-00774
Coronary interventions
Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions
Kelbæk H, Yeh R, Engstrøm T, Neumann F, Serruys P, Windecker S, Belardi J, Qiao S, Xu B, Liu M, Silber S
March 19, 2021 | 10.4244/EIJ-D-19-00866
Coronary interventions
Online three-dimensional OFDI-guided versus angiography-guided PCI in bifurcation lesions: design and rationale of the randomised OPTIMUM trial
Miyazaki Y, Muramatsu T, Asano T, Katagiri Y, Sotomi Y, Nakatani S, Takahashi K, Kogame N, Higuchi Y, Ishikawa M, Kyono H, Yano M, Ozaki Y, Serruys P, Okamura T, Onuma Y
March 19, 2021 | 10.4244/EIJ-D-18-00902
Coronary interventions
Age and Functional Relevance of Coronary Stenosis: a Post-Hoc Analysis of the ADVISE II Trial
Faria D, Lee J, van der Hoef T, Mejía-Rentería H, Echavarría-Pinto M, Baptista S, Cerrato E, García-García H, Davies J, Onuma Y, Samady H, Piek J, Serruys P, Lerman A, Escaned J
March 16, 2021 | 10.4244/EIJ-D-20-01163
Coronary interventions
Neointimal hyperplasia of ultra-thin stents with microcrystalline sirolimus or durable polymer everolimus-eluting stents: 6- and 24-month results of the DESSOLVE III OCT study
Milewski K, Takahashi K, Asano T, Katagiri Y, Hochul M, Buszman P, Tomaniak M, Gorycki B, Zurakowski A, Janas A, Mlodziankowski A, Kachel M, Wykrzykowska J, Wijns W, de Winter R, Buszman P, Onuma Y, Serruys P
February 19, 2021 | 10.4244/EIJ-D-18-01201
Coronary interventions in 2020: the year in review
Lunardi M, Gao C, Hara H, Ono M, Kawashima H, Wang R, Wijns W, Serruys P, Onuma Y
February 5, 2021 | 10.4244/EIJ-D-20-01343
Coronary interventions
Procedural characteristics and clinical outcomes in patients undergoing percutaneous coronary intervention for left main trifurcation disease: the EXCEL trial
Kandzari D, Gershlick A, Serruys P, Leon M, Morice M, Simonton C, Lembo N, Mansour S, Sabaté M, Sabik J, Kappetein A, Dressler O, Stone G
December 18, 2020 | 10.4244/EIJ-D-19-00686
Coronary interventions
Bioresorbable vascular scaffolds versus everolimus-eluting stents: a biomechanical analysis of the ABSORB III Imaging substudy
Kumar A, Gogas B, Thompson E, Burnett G, Molony D, Hosseini H, Chandran K, Lefieux A, Honda Y, Lee J, Serruys P, Kereiakes D, Stone G, Samady H
December 18, 2020 | 10.4244/EIJ-D-19-01128
Coronary interventions
A randomised controlled trial of the sirolimus-eluting biodegradable polymer ultra-thin Supraflex stent versus the everolimus-eluting biodegradable polymer SYNERGY stent for three-vessel coronary artery disease: rationale and design of the Multivessel TALENT trial
Hara H, Gao C, Kogame N, Ono M, Kawashima H, Wang R, Morel M, O'Leary N, Sharif F, Möllmann H, Reiber J, Sabaté M, Zaman A, Wijns W, Onuma Y, Serruys P
December 18, 2020 | 10.4244/EIJ-D-20-00772
Coronary interventions
BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: three-year clinical outcomes of the PIONEER trial
Chang C, Kogame N, Asano T, von Birgelen C, Sabaté M, Onuma Y, Serruys P
December 4, 2020 | 10.4244/EIJ-D-19-00566
Coronary interventions
Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial
Onuma Y, Chevalier B, Ono M, Cequier A, Dudek D, Haude M, Carrié D, Sabaté M, Windecker S, Rapoza R, West N, Reith S, de Sousa Almeida M, Campo G, Iniguez-Romo A, Serruys P
December 4, 2020 | 10.4244/EIJ-D-20-00024

Latest news

NEW ISSUE
PCR London Valves Edition: state of the art on transcatheter treatment for tricuspid valve disease, a mini focus on TR; coronary access after TAVI and more…
November 19, 2021
STATE OF THE ART
Transcatheter treatment for tricuspid valve disease
Fabien Praz et al.
November 19, 2021
AHEAD OF PRINT
Long-term impact of OCT-assessed suboptimal stent deployment
Francesco Prati et al.
November 25, 2021
EDITORIAL
Percutaneous tricuspid valve annuloplasty: additional data and remaining questions
Nicole Karam et al.
November 23, 2021
EDITORIAL
Bioprosthetic valve fracture: haemodynamically effective but safe and clinically necessary?
Josep Rodés-Cabau et al.
November 23, 2021
EDITORIAL
Understanding the past, getting prepared for the future. (Going from in vivo to in vitro to in silico)
Patrick W. Serruys
November 23, 2021
AHEAD OF PRINT
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Francesco Moroni et al.
November 18, 2021
Coronary
Valvular disease
Heart failure
Peripheral
Hypertension
Stroke